225 related articles for article (PubMed ID: 32036421)
1. Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs.
Pastore D; Bruno B; Carluccio P; De Candia MS; Mammoliti S; Borghero C; Chierichini A; Pavan F; Casini M; Pini M; Nassi L; Greco R; Tambaro FP; Stefanoni P; Console G; Marchesi F; Facchini L; Mussetti A; Cimminiello M; Saglio F; Vincenti D; Falcioni S; Chiusolo P; Olivieri J; Natale A; Faraci M; Cesaro S; Marotta S; Proia A; Donnini I; Caravelli D; Zuffa E; Iori AP; Soncini E; Bozzoli V; Pisapia G; Scalone R; Villani O; Prete A; Ferrari A; Menconi M; Mancini G; Gigli F; Gargiulo G; Bruno B; Patriarca F; Bonifazi F
Ann Hematol; 2020 Apr; 99(4):867-875. PubMed ID: 32036421
[TBL] [Abstract][Full Text] [Related]
2. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Koch S; Wein A; Siebler J; Boxberger F; Neurath MF; Harich HD; Hohenberger W; Dörje F
Support Care Cancer; 2013 Sep; 21(9):2395-402. PubMed ID: 23568765
[TBL] [Abstract][Full Text] [Related]
4. Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO).
Aapro M; Caprariu Z; Chilingirov P; Chrápavá M; Curca RO; Gales L; Grigorescu AC; Huszno J; Karlínová B; Kellnerová R; Malejčíková M; Marinca M; Petru E; Płużanski A; Pokorná P; Pribulova Z; Rubach M; Steger GG; Tesařová P; Valekova L; Yordanov N; Walaszkowska-Czyz A
Eur J Cancer; 2022 May; 166():126-133. PubMed ID: 35290913
[TBL] [Abstract][Full Text] [Related]
5. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients.
Razvi Y; Chan S; McFarlane T; McKenzie E; Zaki P; DeAngelis C; Pidduck W; Bushehri A; Chow E; Jerzak KJ
Support Care Cancer; 2019 Jan; 27(1):87-95. PubMed ID: 30284039
[TBL] [Abstract][Full Text] [Related]
6. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey.
Aapro M; Ruffo P; Panteri R; Costa S; Piovesana V
Cancer Rep (Hoboken); 2018 Dec; 1(4):e1127. PubMed ID: 32729252
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses.
Clark-Snow R; Affronti ML; Rittenberg CN
Support Care Cancer; 2018 Feb; 26(2):557-564. PubMed ID: 28871358
[TBL] [Abstract][Full Text] [Related]
9. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Einhorn LH; Rapoport B; Navari RM; Herrstedt J; Brames MJ
Support Care Cancer; 2017 Jan; 25(1):303-308. PubMed ID: 27815710
[TBL] [Abstract][Full Text] [Related]
10. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice.
Jordan K; Gralla R; Jahn F; Molassiotis A
Eur J Pharmacol; 2014 Jan; 722():197-202. PubMed ID: 24157984
[TBL] [Abstract][Full Text] [Related]
11. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO).
Girmenia C; Barosi G; Piciocchi A; Arcese W; Aversa F; Bacigalupo A; Bandini G; Bosi A; Busca A; Castagnola E; Caselli D; Cesaro S; Ciceri F; Locasciulli A; Locatelli F; Mikulska M; Pagano L; Prete A; Raiola AM; Rambaldi A
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1080-8. PubMed ID: 24582783
[TBL] [Abstract][Full Text] [Related]
12. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group.
Araz M; Karaagac M; Korkmaz L; Beypinar I; Uysal M
Curr Probl Cancer; 2019 Aug; 43(4):344-353. PubMed ID: 30497851
[TBL] [Abstract][Full Text] [Related]
13. Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
Cabanillas Stanchi KM; Vek J; Schlegel P; Rupprecht JV; Flaadt T; Weber S; Michaelis S; Lang P; Handgretinger R; Döring M
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1089-1100. PubMed ID: 32056007
[TBL] [Abstract][Full Text] [Related]
14. Fixed Combination Antiemetic: A Literature Review on Prevention of Chemotherapy-Induced Nausea and Vomiting Using Netupitant/Palonosetron.
Clark-Snow RA; Vidall C; Börjeson S; Jahn P
Clin J Oncol Nurs; 2018 Apr; 22(2):E52-E63. PubMed ID: 29547597
[TBL] [Abstract][Full Text] [Related]
15. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-Induced Nausea and Vomiting Prophylaxis: Practice Within the Children's Oncology Group.
Patel P; Robinson PD; Orsey A; Freedman JL; Langevin AM; Woods D; Sung L; Dupuis LL
Pediatr Blood Cancer; 2016 May; 63(5):887-92. PubMed ID: 26864262
[TBL] [Abstract][Full Text] [Related]
17. Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.
De Laurentiis M; Bonfadini C; Lorusso V; Cilenti G; Di Rella F; Altavilla G; Otero M; Ardizzoia A; Marchetti P; Peverelli G; Amoroso D; Vecchio S; Fiorio E; Orecchia S
Support Care Cancer; 2018 Dec; 26(12):4021-4029. PubMed ID: 29943152
[TBL] [Abstract][Full Text] [Related]
18. Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines.
McKenzie E; Zaki P; Raman S; Olson R; McFarlane T; DeAngelis C; Chan S; Pidduck W; Razvi Y; Bushehri A; Chow E
Support Care Cancer; 2019 Mar; 27(3):783-791. PubMed ID: 30607675
[TBL] [Abstract][Full Text] [Related]
19. [Region-wide professional practice evaluation with regards to antiemetic prescription into chemotherapy-induced nausea and vomiting].
Tavernier J; Jouannet-Romaszko M; Bertucat H; Marchiset N; Bahadoor M; Chevrier R
Bull Cancer; 2016; 103(7-8):622-31. PubMed ID: 27178880
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy.
Uchida M; Nakamura T; Shima T; Mori Y; Yoshimoto G; Kato K; Shimokawa M; Hosohata K; Miyamoto T; Akashi K
Pharmazie; 2019 Apr; 74(4):250-254. PubMed ID: 30940311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
